Probiotic Desulfovibrio piger for adults with long-standing type 1 diabetes
Tests the probiotic Desulfovibrio piger against placebo in adults with long-standing type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes
Key facts
- Where
- Amsterdam, NetherlandsSee the 2 sites
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsTaking people
- Diabeter Centrum AmsterdamAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Trial code
- NCT07585994
- Record updated
- 14 May 2026
- Original description
The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.Read full original descriptionShow less
Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes
The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.
Inclusion: Males or females, age >18 years; A diagnosis of type 1 diabetes, with duration of more than 5 years, with minimally one of antiGAD65, IA2, ZnT8 autoantibodies present assessed at diagnosis or routine visits at Diabeter Centrum; Evidence of remaining residual beta cell function with detectable UCPCR (more than 0.01 nmol/mmol C-peptide/creatinine ratio) and or fasting plasma C-peptide more than 0.2 mmol/L; BMI 18-30 kg/m2.
Exclusion: Use of antibiotics or proton-pump inhibitors within the last three months before screening or during study period; Use of other probiotic supplementation within the last month before screening or during study period; Smoking or illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period; A history of cholecystectomy; Overt untreated gastrointestinal disease, inflammatory bowel disease or abnormal bowel habits; Evidence for comprised immunity (HIV infection, chemotherapy, other autoimmune diseases, systemic anti-inflammatory therapy); History of cardiovascular disaeses (CVD) events; Kidney failure (eGFR <15ml.min/1.73m2), dialysis, kidney transplantation,; Absence of a large bowel (ie colostomy); Hepatic enzymes>2.5 higher than the upper limit of normal range, determined during MARVEL visits/routine visits; Inability or unwillingness to donate feces or urine; Alcohol abuse (equal or above 21 units per week); Inability or unwillingness to provide informed consent.